Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy

@article{Silberstein2003ErgotamineAD,
  title={Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy},
  author={Stephen D. Silberstein and Douglas C Mccrory},
  journal={Headache: The Journal of Head and Face Pain},
  year={2003},
  volume={43}
}
Ergotamine and dihydroergotamine share structural similarities with the adrenergic, dopaminergic, and serotonergic neurotransmitters. As a result, they have wide‐ranging effects on the physiologic processes that they mediate. Ergotamine and dihydroergotamine are highly potent at the 5‐HT1B and 5‐HT1D antimigraine receptors and, as a consequence, the plasma concentrations that are necessary to produce the appropriate therapeutic and physiologic effects are very low. The broad spectrum of… Expand
Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan – Basic Science in Relation to Migraine Treatment
The 5‐hydroxytryptamine (5‐HT) receptor family mediates the effects of several drugs highly effective in migraine primarily by activating 5‐HT1B, 5‐HT1D, and 5‐HT1F receptors. Ergotamine,Expand
Binding Interactions of Ergotamine and Dihydroergotamine to 5-Hydroxytryptamine Receptor 1B (5-HT1b) Using Molecular Dynamics Simulations and Dynamic Network Analysis
TLDR
Using the detailed dynamic information from the analysis, predictions for possible modifications to DHE and ERG that yielded 5 derivatives that might have more favorable binding energies and reduced structural fluctuations were made. Expand
Dihydroergotamine (DHE) – Is there a place for its use?
TLDR
Most clinical data confirm that the drug is still an important element of contemporary migraine therapy, especially in cases when conventional medicine fails, and its role in modern therapy based on available clinical trials is confirmed. Expand
Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.
TLDR
Novel antimigraine drugs devoid of vascular (side) effects are being explored, including calcitonin gene-related peptide receptor antagonists and 5-HT(1F) receptor agonists, which do not have direct vasoconstrictor effects but may well induce indirect vascular effects by inhibiting or otherwise modulating the responses to endogenous vasoactive substances. Expand
Outlining migrainous through dihydroergotamine–serotonin receptor interactions using quantum biochemistry
Since the early days of migrainous research, serotonin receptors (5-HTR) have been considered a major target of drugs, and the 5-HT1B and 5-HT1D agonists have been among the most marketed ones forExpand
Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs
TLDR
Although the triptans are very effective in treating migraine attacks, their shortcomings have stimulated the search for novel drugs, and the focus is on 5-HT1F receptor agonists, which seem devoid of vascular side effects. Expand
An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies
TLDR
The present review summarizes the current knowledge on the role of the above neuropeptides in the trigeminovascular system, and migraine pathophysiology, and discusses some issues related with the mechanisms of action and side effects concerns that could be elicited when targeting the CGRPergic, PACAPergic, oxytocinergic and orexinergic systems. Expand
Orally inhaled dihydroergotamine: reviving and improving a classic
TLDR
The new orally inhaled DHE appears to be as effective with a better side effect profile compared with intravenous DHE, thus eliminating the complexities typically associated with DHE administration. Expand
Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors
TLDR
It is suggested that DHE-induced inhibition of the perivascular sensory CGRPergic outflow may facilitate DHE’s vasoconstrictor properties resulting in an increased vascular resistance. Expand
Investigation of Nocifensive and Cellular Effects of Dihydroergotamine in a Model of Chronic Migraine
TLDR
Results from this study provide evidence that DHE, but not sumatriptan, can inhibit nociception caused by prolonged activation of trigeminal neurons and the inhibitory effect is likely to involve suppressing development of central sensitization. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 148 REFERENCES
Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
TLDR
Both DHE and ET are safe and effective when used in recommended doses, and nearly 50 years of clinical experience without major safety problems allows a high level of confidence in their clinical use. Expand
Dihydroergotamine: Pharmacokinetics, Pharmacodynamics, and Mechanism of Venoconstrictor Action in Beagle Dogs
TLDR
Experimental data support the suggestion that the long duration of the DHE-induced venoconstriction is due to an extremely slow dissociation of the drug from its receptor sites on the venous smooth muscle cell, and to the formation of active metabolites. Expand
Localization of 3H‐Dihydroergotamine‐binding sites in the cat central nervous system: Relevance to migraine
TLDR
Using in vitro and ex vivo autoradiographic techniques, the localization of specific binding sites for 3H‐dihydroergotamine in the cat brain has been examined, finding the highest density of binding sites was found in the dorsal and medial raphe nuclei of the midbrain. Expand
The Effect of Ergotamine and Dihydroergotamine on Cerebral Blood Flow in Man
TLDR
This study did not support the belief that ergot alkaloids should be withheld from patients during attacks of classic migraine, and the discrepancy in the peripheral effects of ergotamine and dihydroergotamine might also be of clinical importance. Expand
Safety and Efficiency of Ergotamine Tartrate and Dihydroergotamine in the Treatment of Migraine and Status Migrainosus.
TLDR
The background information for the Practice Parameter is provided, and the appropriate use of ergotamine tartrate and DHE in the treatment of (1) migraine and (2) status migrainosus is defined. Expand
Coronary side-effect potential of current and prospective antimigraine drugs.
TLDR
All current and prospective antimigraine drugs contract the human coronary artery in vitro, but in view of low efficacy, these drugs are unlikely to cause myocardial ischemia at therapeutic plasma concentrations in healthy subjects. Expand
Pharmacological actions of the main metabolites of dihydroergotamine
TLDR
It is concluded that DHE metabolites with considerable venoconstrictor activity may contribute to the selective therapeutic action of DHE. Expand
DOUBLE‐BLIND CLINICAL EVALUATION OF THE EFFICACY AND SAFETY OF ERGOSTINE‐CAFFEINE, ERGOTAMINE‐CAFFEINE, AND PLACEBO IN MIGRAINE HEADACHE
TLDR
The therapeutic effect of ergotamine tartrate depends upon its ability to prolong a vasoconstriction action, thus interrupting the pain producing mechanism. Expand
Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache
  • V. Perrin
  • Medicine
  • Clinical pharmacokinetics
  • 1985
TLDR
Efficacy is greatest after parenteral administration, although adverse effects may make the rectal or inhaled routes preferable, and there is some evidence to suggest that good responses are associated with plasma concentrations of 0.2 ng/ml or above within one hour of administration. Expand
Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
TLDR
Further studies are necessary to compare dihydroergotamine with sumatriptan for acute migraine and with beta-blockers in prophylaxis to determine its future role in migraine therapy. Expand
...
1
2
3
4
5
...